Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
2005 1
2007 1
2008 2
2010 2
2011 3
2012 1
2014 1
2015 2
2016 2
2017 1
2018 2
2020 4
2021 2
2022 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
"Going Mobile"-increasing the reach of parent-mediated intervention for toddlers with ASD via group-based and virtual delivery.
Brian J, Solish A, Dowds E, Roth I, Bernardi K, Perry K, Daoud S, Jilderda S, MacWilliam S, Smith IM, Zwaigenbaum L, Bryson S. Brian J, et al. J Autism Dev Disord. 2022 Dec;52(12):5207-5220. doi: 10.1007/s10803-022-05554-7. Epub 2022 May 24. J Autism Dev Disord. 2022. PMID: 35608785 Free PMC article.
We examined uptake and outcomes from 82 families participating in a parent-mediated intervention comprising group-based learning and individual coaching, delivered either in-person (n = 45) or virtually (n = 37). Parents from diverse linguistic, ethnic, and educatio …
We examined uptake and outcomes from 82 families participating in a parent-mediated intervention comprising group-based learning and individ …
ASDS guidelines of care: injectable fillers.
Alam M, Gladstone H, Kramer EM, Murphy JP Jr, Nouri K, Neuhaus IM, Spencer JM, Spenceri E, Van Dyke S, Ceilley RI, Lee KK, Menaker G, Monheit GD, Orentreich DS, Raab B, Smith KC, Solish NJ; American Society for Dermatologic Surgery. Alam M, et al. Dermatol Surg. 2008 Jun;34 Suppl 1:S115-48. doi: 10.1111/j.1524-4725.2008.34253.x. Dermatol Surg. 2008. PMID: 18547175 No abstract available.
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses of the Phase III Clinical Study Data.
Solish N, Ascher B, Avelar RL, Bertucci V, Bodokh I, Carruthers J, Cartier H, Delmar H, Denfeld R, Heckmann M, Hedén P, Hilton S, Inglefield C, Ogilvie P, Rzany BJ, Sattler G, Sebastian M, Swift A, Trévidic P. Solish N, et al. Aesthet Surg J. 2022 Dec 14;42(12):1460-1469. doi: 10.1093/asj/sjac210. Aesthet Surg J. 2022. PMID: 35922149 Free PMC article. Clinical Trial.
METHODS: Post-hoc analyses were performed on the subpopulation of male patients treated with either a single dose of 20 U prabotulinumtoxinA (n = 25) or 20 U onabotulinumtoxinA (n = 31) in the EVB-003 Phase III glabellar line clinical study. ...
METHODS: Post-hoc analyses were performed on the subpopulation of male patients treated with either a single dose of 20 U prabotulinumtoxinA …
Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines.
Solish N, Kane MAC, Biesman BS, Brown J, Gallagher CJ. Solish N, et al. Aesthet Surg J. 2023 Nov 9;43(Suppl 1):S1-S9. doi: 10.1093/asj/sjab362. Aesthet Surg J. 2023. PMID: 36095026 Free PMC article.
METHODS: This study involved the post hoc analysis of adult patients from the Phase 2a forehead lines (FHL, N = 60) and open-label safety (OLS, N = 175) studies who received a single dose of DAXI 40 U to the glabella and for whom facial photographs were taken at res …
METHODS: This study involved the post hoc analysis of adult patients from the Phase 2a forehead lines (FHL, N = 60) and open-label sa …
PrabotulinumtoxinA for the treatment of glabellar lines in adults, 65 years of age and older: The fourth in a series of post hoc analyses of the phase III clinical study data.
Cox SE, Ascher B, Avelar RL, Beer KR, Carruthers J, Cartier H, Fagien S, Solish N. Cox SE, et al. J Cosmet Dermatol. 2023 Jun;22(6):1745-1756. doi: 10.1111/jocd.15783. Epub 2023 Apr 27. J Cosmet Dermatol. 2023. PMID: 37102990 Clinical Trial.
METHODS: Post hoc analyses were performed on all patients who had been treated with a single dose of 20 U prabotulinumtoxinA in the three 150-day, placebo-controlled Phase III glabellar line clinical studies. Patients were grouped by age: 65 years (n = 70) versus <65 ye …
METHODS: Post hoc analyses were performed on all patients who had been treated with a single dose of 20 U prabotulinumtoxinA in the three 15 …
30 results